Loading
Lung Cancer Treatments and Mutations / Lung Cancer Diagnosis and Treatment · Journal article
Case Reports in Oncology · August 13, 2026
Early or partial results. Treat as a signal, not a conclusion.
Two case reports describe prolonged progression-free survival and minimal toxicity in advanced NSCLC patients treated with nab-paclitaxel combined with bevacizumab ± anti-PD-1 checkpoint inhibitor in a low-dose, extended-interval maintenance schedule. This is a descriptive report that raises the hypothesis that such a strategy warrants prospective testing, but does not establish efficacy or generalizability.
Case reports. Two patients with advanced NSCLC: Case 1 ALK-positive; Case 2 driver-negative, treated with nab-paclitaxel-based maintenance regimens.. Intervention: Case 1: nab-paclitaxel + bevacizumab every 4 weeks. Case 2: nab-paclitaxel + bevacizumab + toripalimab every 6–8 weeks.. n = 2.
Case 1 (ALK-positive): nab-paclitaxel + bevacizumab sustained for more than 48 months with maintained partial response Case 2 (driver-negative): nab-paclitaxel + bevacizumab + toripalimab (anti-PD-1) sustained for 24 months with maintained partial response Both cases reported minimal toxicity with no grade ≥3 adverse events and preserved quality of life
No endpoint definitions, censoring patterns, or reasons for treatment discontinuation reported. Both cases reported minimal toxicity with no grade ≥3 adverse events and preserved quality of life
These cases do not establish a change in practice. They may prompt consideration of prospective trials but should not guide treatment decisions in the absence of comparative efficacy data or safety profiles from controlled studies.
Two uncontrolled case reports with prolonged outcomes suggest a potential maintenance strategy, but lack comparator arms, prospective design, and power to establish efficacy or safety profiles.
As stated by the source record.
Quoted from the source exactly as published.
These cases do not establish a change in practice. They may prompt consideration of prospective trials but should not guide treatment decisions in the absence of comparative efficacy data or safety profiles from controlled studies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background. The role of nab-paclitaxel in non-small cell lung cancer (NSCLC) maintenance therapy remains underexplored, particularly in combination with anti-angiogenic agents and immunotherapy. We present two cases of advanced NSCLC achieving prolonged progression-free survival (PFS) with nab-paclitaxel-based regimens. Case presentation. Case 1 (ALK-positive) received nab-paclitaxel+ bevacizumab every 4 weeks for more than 48 months. Case 2 (driver-negative) received nab-paclitaxel + bevacizumab + toripalimab every 6–8 weeks for 24 months. Both patients maintained partial regression disease, minimal toxicity (no grade ≥3 adverse events), and preserved quality of life. Conclusion. The literature review highlights synergistic mechanisms of chemotherapy, anti-angiogenesis, and immunotherapy, supported by trials such as IMpower150 and KEYNOTE-407. Low-dose, extended-interval nab-paclitaxel combined with anti-angiogenesis and immunotherapy may offer a feasible maintenance strategy, warranting validation in prospective trials.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.